{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:57:24Z","timestamp":1762106244295,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100025169","name":"Institut Kanser Negara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.vhri.2024.101028","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T16:49:34Z","timestamp":1722098974000},"page":"101028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Health-Related Quality of Life and Economic Analysis of Olanzapine Versus Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Malaysia"],"prefix":"10.1016","volume":"44","author":[{"given":"Nurul Suhaida","family":"Badarudin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noraida","family":"Mohamed Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurul Ain","family":"Mohd Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azmi Nor Mohd Farez","family":"Ahmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farida","family":"Islahudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhana","family":"Yusak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syahir","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamarun Neasa Begam","family":"Mohd Kassim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.vhri.2024.101028_bib1","first-page":"S266","article-title":"Chemotherapy-induced nausea and vomiting: roles of pharmacists and formulary decision makers","volume":"23","author":"McCullough","year":"2017","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.vhri.2024.101028_bib2","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","article-title":"Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2018 quality of life","volume":"20","author":"Fern\u00e1ndez-Ortega","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2024.101028_bib3","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am Health Drug Benefits"},{"issue":"2","key":"10.1016\/j.vhri.2024.101028_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14737167.2016.1146594","article-title":"Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments","volume":"16","author":"Schwenkglenks","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00520-014-2373-2","article-title":"Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries","volume":"23","author":"Hsieh","year":"2015","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.vhri.2024.101028_bib6","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1007\/s00520-022-06956-0","article-title":"A\u00a0retrospective study on chemotherapy-induced nausea and vomiting in highly\/moderately emetogenic chemotherapy: incidence and prescribing practice","volume":"30","author":"Badarudin","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","article-title":"MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients","volume":"27","author":"Razvi","year":"2019","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.vhri.2024.101028_bib8","first-page":"145","article-title":"Cheaper options in the prevention of chemotherapy-induced nausea and vomiting","volume":"2","author":"Gyawali","year":"2016","journal-title":"J\u00a0Glob Oncol"},{"key":"10.1016\/j.vhri.2024.101028_bib9","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1038\/srep04813","article-title":"A\u00a0meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.vhri.2024.101028_bib11","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00520-023-08221-4","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents","volume":"32","author":"Herrstedt","year":"2023","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00520-023-08224-1","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting","volume":"32","author":"Rapoport","year":"2023","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.vhri.2024.101028_bib15","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1634\/theoncologist.2018-0140","article-title":"Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"24","author":"Yokoe","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.vhri.2024.101028_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2024.101028_bib17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","volume":"25","author":"Bajpai","year":"2024","journal-title":"Lancet Oncol"},{"issue":"50","key":"10.1016\/j.vhri.2024.101028_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032116","article-title":"The emerging role of olanzapine in paediatric CINV control: a review","volume":"101","author":"Baru\u0161i\u0107","year":"2022","journal-title":"Med (Baltim)"},{"issue":"2","key":"10.1016\/j.vhri.2024.101028_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/SPC.0000000000000206","article-title":"Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine","volume":"10","author":"Bosnjak","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"issue":"3","key":"10.1016\/j.vhri.2024.101028_bib20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study","volume":"27","author":"Chanthawong","year":"2019","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.vhri.2024.101028_bib21","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1007\/s00520-020-05977-x","article-title":"Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients","volume":"29","author":"Chow","year":"2021","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40780-022-00246-x","article-title":"Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy","volume":"8","author":"Kondo","year":"2022","journal-title":"J\u00a0Pharm Health Care Sci"},{"issue":"5","key":"10.1016\/j.vhri.2024.101028_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J\u00a0Pain Symptom Manag"},{"issue":"10","key":"10.1016\/j.vhri.2024.101028_bib24","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.vhri.2024.101028_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1573408015666190620165507","article-title":"Should olanzapine be advocated over conventional antiemetics for the prevention of chemotherapy-induced nausea and vomiting? An updated meta-analysis of randomized control trials","volume":"15","author":"Bahbah","year":"2019","journal-title":"Curr Enzyme Inhib"},{"key":"10.1016\/j.vhri.2024.101028_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A\u00a0randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4143\/crt.2017.577","volume":"51","author":"Jeon","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.vhri.2024.101028_bib29","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2147\/CMAR.S254398","article-title":"Efficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: a retrospective study","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"12","key":"10.1016\/j.vhri.2024.101028_bib30","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1007\/s00520-020-05443-8","article-title":"Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy","volume":"28","author":"Hirose","year":"2020","journal-title":"Support Care Cancer"},{"issue":"27","key":"10.1016\/j.vhri.2024.101028_bib31","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2024.101028_bib32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cncr.23594","article-title":"How do patient expectancies, quality of life, and postchemotherapy nausea interrelate?","volume":"113","author":"Colagiuri","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.vhri.2024.101028_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib34","first-page":"35","article-title":"Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy","volume":"4","author":"Decker","year":"2006","journal-title":"J\u00a0Support Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2024.101028_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","article-title":"Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients","volume":"45","author":"Pickard","year":"2007","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.vhri.2024.101028_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0266462306051051","article-title":"Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review","volume":"22","author":"R\u00e4s\u00e4nen","year":"2006","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vhri.2024.101028_bib37","series-title":"Encyclopedia of Health Economics","first-page":"341","article-title":"Multiattribute utility instruments and their use","author":"Richardson","year":"2014"},{"issue":"1","key":"10.1016\/j.vhri.2024.101028_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00520-014-2376-z","article-title":"Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice","volume":"23","author":"Kim","year":"2015","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.vhri.2024.101028_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oncolo\/oyac240","article-title":"Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles","volume":"28","author":"Navari","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.vhri.2024.101028_bib40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/03007995.2011.556603","article-title":"Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC\/MEC\/HEC)","volume":"27","author":"Schwartzberg","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.vhri.2024.101028_bib41","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.31557\/APJCP.2022.23.6.2137","article-title":"Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor antagonist","volume":"23","author":"Sukauichai","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.vhri.2024.101028_bib42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","article-title":"Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study","volume":"156","author":"Iihara","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992400061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992400061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:49:35Z","timestamp":1749264575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992400061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"alternative-id":["S221210992400061X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101028","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life and Economic Analysis of Olanzapine Versus Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Malaysia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101028"}}